The Federal Institute of Medical Devices and Equipment (VNIIIMT) has published methodological recommendations that address the practical aspects of preparing annual reports on clinical monitoring of medical devices. It is important to note that this document is for reference only and does not have the status of a regulatory legal act. Deviation from the provisions set forth herein does not result in administrative or other liability.
The recommendations are aligned with Russian Ministry of Health orders No. 540n and No. 541n of May 26, 2026, which came into effect in September 2026 and replaced similar regulations issued four years earlier.
The essence of clinical monitoring
- The manufacturer is required to submit an annual report to Roszdravnadzor electronically for three years, beginning with the year following the year of product registration. This procedure is established by Order No. 541n.
- The deadline for submission is February 1 of the reporting year.
- The monitoring is based on clinical data collected during actual use of the product in Russian medical organizations ; no new research is required for this.
- The prepared report is reviewed by VNIIIMT within 120 working days, and the final decision rests with Roszdravnadzor.
What to include in the report and how it is evaluated
The text of the recommendations lists the sections that should be reflected in the report: a list of residual risks, data on adverse events and corrective measures taken, monitoring goals and plan, clinical materials indicating medical organizations, and a conclusion on the safety and effectiveness of the product.
The document’s authors specifically state that an analysis of adverse events and complaints is not the entire report. Both positive and negative experiences with the product are subject to evaluation. International data may be cited only as supplementary material, and reviews from medical organizations not supported by clinical data will not be considered proof of safety and efficacy.
The recommendations also distinguish three types of reports: initial, follow-up, and final. The final report includes information for three years, with a consolidated analysis of the accumulated data.
When monitoring expands
Additional monitoring after changes to the registration dossier becomes necessary if the manufacturer expands the product line or indications, changes the patient population, or changes the implantation method. One of the new features is mandatory monitoring when adding a software module that utilizes artificial intelligence technologies.
Monitoring can also be extended for another three years: this occurs if the collected data is insufficient or the required corrective actions have not been completed. If the manufacturer misses the reporting deadline, registration may be suspended for 30 business days, during which time the document can still be submitted.